Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

392
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
392
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

233
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

727
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
727
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

436
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
436

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'We're not going to start lifting stones now…': Stakeholder perspectives on the role of psychometric methods in outcome measurement.

The British journal of clinical psychology·2026
Same author

Type 2 diabetes outcomes in patients with Posttraumatic stress disorder and psychiatric comorbidity.

Diabetes research and clinical practice·2026
Same author

Validation of a two-item short form of the perceived health competence scale.

Journal of patient-reported outcomes·2025
Same author

Do complex psychometric analyses really matter? Comparing multiple approaches using individual participant data from antidepressant trials.

Psychological medicine·2025
Same author

Psychiatric multimorbidity in heart failure.

Journal of psychosomatic research·2025
Same author

Determining sample size for pilot trials: a tutorial.

BMJ (Clinical research ed.)·2025

Related Experiment Video

Updated: Jan 7, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

499

Patient-reported substance use in heart failure.

Kenneth E Freedland1, Brian C Steinmeyer1, Judith A Skala1

  • 1Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.

Heart & Lung : the Journal of Critical Care
|December 27, 2025
PubMed
Summary

Substance use disorders are common in heart failure patients, affecting nearly half of those studied. These conditions are linked to smoking, COPD, and poor quality of life, highlighting a need for integrated care.

Keywords:
Heart failureInterview, psychologicalSocial determinants of healthSubstance abuse detectionSubstance-related disorders

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K

Related Experiment Videos

Last Updated: Jan 7, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

499
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K

Area of Science:

  • Cardiology
  • Psychiatry
  • Public Health

Background:

  • Substance use disorders (SUDs) are common in heart failure (HF) patients, complicating care.
  • Previous research relied on epidemiological data; this study used in-depth interviews.
  • Understanding patient-reported SUDs and polysubstance use in HF is crucial.

Purpose of the Study:

  • To document the prevalence of patient-reported substance use comorbidities in heart failure (HF) patients.
  • To identify the extent of polysubstance use within this population.
  • To explore associations between SUDs and other health factors.

Main Methods:

  • 362 heart failure patients were interviewed within two weeks of hospital discharge.
  • The NetSCID-5 interview assessed substance use and psychiatric disorders.
  • Social determinants of health, stress, and quality of life were also measured.

Main Results:

  • Alcohol (26%), stimulant (10%), and cannabis (6%) use disorders were prevalent.
  • Approximately 9% of HF patients reported polysubstance use.
  • SUDs correlated with smoking, COPD, adverse social determinants, and lower quality of life.

Conclusions:

  • Substance use disorders are frequent comorbidities in heart failure patients.
  • Integrated care approaches are necessary for managing these dual conditions.
  • Further research into prevention and treatment strategies for SUDs in HF is essential.